top of page

NCI-2019-07439

EA1181 (CompassHER2-pCR) Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)


This is a part of a bigger research study called CompassHER2 Trials. The goal of these trials is to find the best ways to treat a specific type of breast cancer called HER2-positive breast cancer. In this part of the study, called EA1181 CompassHER2-pCR, they're focusing on two different phases of treatment for this type of cancer. Part 1: Preoperative THP: Preoperative: This means before surgery. THP: This stands for three different medicines: Taxol (T), Herceptin (H), and Perjeta (P). These medicines are used to treat HER2-positive breast cancer. So, in this part, they're giving these three medicines (Taxol, Herceptin, and Perjeta) to patients before they have surgery to remove the cancer. Part 2: Postoperative HP Postoperative: This means after surgery. In this part, they're giving these two medicines (Herceptin and Perjeta) to patients after they've had surgery to remove the cancer. The specific group of patients they're looking at are those who have a pathologic complete response. This means that after the treatment, there's no evidence of cancer in the tissue that's been removed during surgery. This is a good sign that the treatment is working well.

HER2-positive breast cancer: It is a type of breast cancer where cancer cells have higher-than-normal levels of HER-2 receptors are called HER-2 positive. These receptors are like tiny doorways on the surface of the cells. HER-2 positive breast cancers tend to grow and spread faster than other kinds, but they also respond well to certain drugs that target the HER-2 receptor.

For more information about the trial, click the link below:

NCI-2019-07439

Clinical Trial Site: Columbia


To see all available clinical trials click here.



Recent Posts

See All

NCI-2023-06503

An open-label, single-arm, Phase 1b/2 study to investigate the safety, efficacy and pharmacokinetics of LS301-IT in female patients undergoing partial mastectomy and sentinel lymph node biopsy (SLNB)

NCI-2022-02453

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer Doctors are conducting a study to test the safety and effectiveness of a new medicine called

NCI-2022-07265

EAY191-N2 Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1 A ComboMATC

bottom of page